Lupin

Price chart

Previous close

₹1,997.00

Open

₹2,008.80

Day high

₹2,036.50

Day low

₹1,991.00

Listed on NSE since 10 September 2001.

Futures and options

Futures, 23 Nov expiry

₹2,019.00

Premium to the share price

+5.80 (+0.29%)

Futures open interest

16,481 contracts (+186 today)

Lot size (NOV 26)

425 shares

Source: NSE, 09-Nov-2026 12:04:38, delayed. Option chain · All futures · Lot sizes

Pivot levels

R3

2,029.30

R2

2,013.10

R1

2,000.60

CPR top

1,986.25

Pivot

1,984.40

CPR bottom

1,982.55

S1

1,971.90

S2

1,955.70

S3

1,943.20

From Friday 6 November’s high, low and close (Yahoo Finance). Arithmetic on past prices, not a forecast.

Market value

₹91,321 Cr

P/E (trailing)

17.60

EPS (trailing)

₹113.48

Price to book

3.80

Dividend yield

0.91%

Return on equity

23.9%

Debt to equity

0.26

Profit margin

16.9%

Beta

0.16

Volume today

4.70 L

Average volume

7.78 L

Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.

Source: Yahoo Finance, from annual reports. Consolidated where reported.

Source: Lupin’s results filed with NSE, consolidated (the whole group). Net profit is the share of Lupin’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.

Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.

Source: Lupin’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It produces, develops, and markets various branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company also offers products in the therapeutic areas of cardiovascular, diabetology, asthama, pediatrics, central nervous system, gastro-intestinal, anti-infectives, anti-TB, cephalosporins, and nonsteroidal anti-inflammatory drug therapies. In addition, it provides chronic therapies, and hospital-based products; products for diabetes and iron supplements for anemia, and a Budesonide-Formoterol combination for asthma. Further, the company is involved in the provision of diagnostics services, and digital healthcare services; and neuro rehabilition business. It operates through network consisting of labs and collection centers. The company has a strategic collaboration with TB Alliance to support the clinical development and commercialization of Telacebec for the treatment of tuberculosis, leprosy, and buruli ulcer. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.

Industry

Drug Manufacturers - Specialty & Generic

Based in

Mumbai

Employees

26,021

Company website · Profile: Yahoo Finance

No headlines name Lupin in the last day or two.

• Dividend - Rs 18 Per Share

  Dividend · ex-date 17 July 2026

• Dividend - Rs 12 Per Share

  Dividend · ex-date 25 July 2025

• Dividend - Rs 8 Per Share

  Dividend · ex-date 16 July 2024

• Dividend - Rs 4 Per Share

  Dividend · ex-date 14 July 2023

• Dividend - Rs 4 Per Share

  Dividend · ex-date 14 July 2022 · record date 15 July 2022

• Dividend - Rs 6.50 Per Share

  Dividend · ex-date 27 July 2021 · record date 28 July 2021

• Annual General Meeting/Dividend - Rs 6 Per Share

  Dividend · ex-date 3 August 2020

• Annual General Meeting/Dividend - Rs 5 Per Share

  Dividend · ex-date 29 July 2019

Source: NSE. Latest first, 8 of 20.